Kirsten Craven

Inside the box: Complementary fragmentation with LC-MS for Metabolite Identification

Feb 7, 2025 | Blogs, Pharma, ZenoTOF 7600 system | 0 comments

Read Time: 2 Minutes

Introduction

Liquid chromatography-mass spectrometry is commonly used for Met ID but confident soft spot identification is not always possible. Imagine the advantage of unambiguous metabolite identification using liquid chromatography-mass spectrometry (LC-MS) reducing the need for additional safety testing during drug discovery. Quickly and easily generate the information you need using routine assays that are robust and efficient, enabling confident decision-making while also saving time and money. Learn more >

Streamline Met ID with additional fragmentation information

Metabolite identification is a key task during drug discovery to establish safety and efficacy of a drug candidate. LC-MS assays for metabolite identification typically use collision-induced dissociation (CID) to fragment ions for structural elucidation, and soft-spot identification. With challenging metabolites, CID doesn’t produce sufficient fragment ions or help with labile modifications and a clear identification cannot be made. This can lead to the need for additional testing to meet regulatory requirements.

What is electron-activated dissociate (EAD)?

EAD is a fragmentation method available on the ZenoTOF 7600 system that causes ions in an LC-MS/MS experiment to fragment in locations that are different from where they fragment with CID, providing additional information to scientists. For metabolite identification, this could mean confident identification of the metabolite and localization of the site of metabolism, removing the need for additional safety testing.

Curious to know more? Watch our on-demand Met ID webinars, here? LINK WILL COME FROM HERE https://sciex.kapost.com/posts/pharma-webinar-content-hub-lp-and-typ

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments